在肺高血压中,P4HA1/HIF1α反循环调节内皮功能障碍
Yunwei Chen1, Yifei Lv1, Meng Yang1
1Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Respiratory research
|November 22, 2025
概括
甘氨酸蛋白P4HA1在肺高血压 (PH) 中被上调. 准P4HA1/HIF1α通路可能为治疗PH及其相关血管重塑提供新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 细胞的新陈代谢
背景情况:
- 肺高血压 (PH) 是一种严重的血管疾病,导致右心力衰竭.
- 糖解蛋白P4HA1在PH病原发生中的作用尚不清楚.
研究的目的:
- 为了研究P4HA1在肺高血压的发病过程中的作用.
- 为了阐明P4HA1/HIF1α信号轴在缺氧诱导的肺血管改造.
主要方法:
- 低毒人类肺动脉内皮细胞 (HPAECs) 的RNA测序.
- 在实验室中对P4HA1进行敲除,以评估对糖解,增殖和迁移的影响.
- 关于HIF1α调节和P4HA1介导稳定性的机制研究.
- 在小鼠PH模型中使用AAV9-shP4HA1进行体内评估.
主要成果:
- 在低氧状态下,P4HA1在HPAEC中升级调节,由HIF1α转录激活.
- P4HA1稳定了HIF1α,形成了一个自我放大循环.
- 在HPAEC中,P4HA1倒置抑制了缺氧诱导的糖解,增殖和迁移.
- 内皮特异性P4HA1敲击减弱的肺血管重塑和改善的右心室功能 in vivo.
结论:
- P4HA1是PH病变的新型贡献者.
- 准P4HA1/HIF1α轴为肺高血压提供了一个潜在的治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Pulmonary Hypertension: Classification and Pathogenesis
533
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
533
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
523
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
523
Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
411
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
411


